The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Recent Study Testing International Formulation Shows Significant Increase in GLP-1 HormoneSALT LAKE CITY, Feb. 04, 2025 ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

Scientists remain puzzled as to why some individuals taking popular weight loss and diabetes medications such as Ozempic and ...

Robert F. Kennedy Jr. sounded concern on the GRAS process and claimed GLP-1s are “miracle drugs” but fell short on the drugs ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance. The approach is especially popular among telemedicine physicians, who ...

After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and ...

The condition appears to be triggered when the optic nerve swells, choking off its blood supply because the nerve's pathway ...

GLP-1 drugs mimic a hormone that sends the brain signals of fullness. Researchers theorize that the drugs could work the same ...

GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...